$GDRX News

Barclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4

UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75

Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5

TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

GoodRx (NASDAQ:GDRX) Q2 2026: Subscription and Pharma Direct Growth Lift Shares Despite Revenue Decline

GoodRx Holdings Raises FY2026 Sales Guidance from $765.000M-$785.000M to $790.000M-$805.000M vs $775.751M Est

GoodRx Holdings Q2 Adj. EPS $0.08, Inline, Sales $200.411M Beat $193.162M Estimate

GoodRx Holdings (GDRX) Pharma Growth Story Meets A Small Fair Value Gap

GoodRx (GDRX) Stock Looks Full On Earnings But Mixed On Value

GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call

GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock?

Is GoodRx (GDRX) Stock Undervalued Right Now?

Q1 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks

GoodRx Holdings, Inc. (GDRX) Strengthens Recurring Revenue Base with Companion

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx Launches Its $14.99 Per Month Subscription Service, GoodRx Companion

GoodRx: Evident Stabilization, But GLP-1 Dependence Is A Risk (Upgrade)

The 5 Most Interesting Analyst Questions From GoodRx’s Q1 Earnings Call

GoodRx Holdings' (NASDAQ:GDRX) Soft Earnings Are Actually Better Than They Appear